Genewity
- Founded
- 2022
- Business Model
- B2B
- Website
- genewity.tech
- Last Round
- GrantMar 2023
- Rounds
- 1
About
Pioneering advanced technologies aimed at revolutionising immune reconstitution for patients with severe immune deficiencies.
Summary
Genewity is a Biotech company, founded in 2022. Its most recent funding was a Grant round in Mar 2023. Investors include European Innovation Council Fund.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2023
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...